DoD Adds Critical Trial Site Center to Novavax Study as JPEO-CBRND Augments Mission for Compelling COVID-19 Vaccines

DoD Adds Critical Trial Site Center to Novavax Study as JPEO-CBRND Augments Mission for Compelling COVID-19 Vaccines TrialsiteN

The Department of Defense continues to contribute prominent trial site centers to the ongoing quest for additional mission-critical COVID-19 vaccines studies. Most recently, vaccine sponsor Novavax, which received $1.6 billion from the U.S. government via Operation Warp Speed (OWS), selected Womack Army Medical Center. Fort Bragg-based Womack now joins five other DoD facilities supporting AstraZeneca’s Phase 3 clinical trial, including Naval Medical Center San Diego, CA; Brooke Army Medical Center; Wilford Hall Ambulatory Surgical Center; Walter Reed National Military Center; and Fort Belvoir Community Hospital. The development of multiple vaccine candidates, representing competition on the market, is a very good thing. It will raise the bar and offer the nation and beyond the most compelling candidates to fight off COVID-19. The DoD trial site participation makes a big difference accessing large numbers of potential patriotic participants. DoD also contributes by supporting the sponsor with funding thanks to the participation of DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency.

The Product

NVK-CoV-2373 represents a more traditional vaccine candidate of the type used to target influenza. As explained by the sponsor, NVX-COV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CCoV-2, the virus that causes COVID-19 disease. The product was developed using the sponsor’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein adjuvanted with Novavax’ patented saponin-based Matrix-M to enhance the immune response and stimulate high levels of neutralizing antibodies. The investigational product contains purified protein antigen and doesn’t replicate nor cause COVID-19.

Novavax Study

TrialSite recently showcased the Novavax study (NCT04611802) involving 30,000 participants in this Phase 3 study including trial site locations from America to Mexico. The sponsor has selected at least 120 trial site locations including the DoD-owned centers. The study started in December and runs through to the estimated completion date of March, 2021, and the final completion date of December 2022.


Participation in the OWS-supported Phase 3 vaccine or monoclonal antibody prevention trials should visit here and select “Volunteer Now” and complete the survey. For military volunteers, once the survey is completed local study site coordinators contact the Military Health System beneficiary volunteers in the select area to determine the match for the study as reported in the DoD’s recent press release.

For the Novavax clinical trial location, see the source for more details on Womack Army Medical Center site code and contact information.